Patient Information Booklet for Patients Switching from Warfarin to Apixaban for Stroke Prevention in NVAF
This booklet is intended only for patients prescribed ELIQUIS for the indication shown. It is not intended to replace the Patient Information Leaflet.
This booklet is intended to be read by patients only after they have been prescribed ELIQUIS. It may be read in its electronic format (PDF) or it may be printed and read.
Switching from warfarin to ELIQUIS should be done under close clinical supervision. Any prescribing decision should only be made by the prescribing healthcare professional on the basis of sound clinical reasons and after appropriate assessment with patient involvement in the
decision-making.
If a Patient Information Booklet is printed, please ensure that:
- It is printed in its entirety. Please do not attempt to print and use individual pages in isolation, as it has been designed to be printed in its entirety
- Its content is not edited or altered in any way
- It is in colour
- It is printed in A4 size
- The pages are placed in the correct order as per the page numbering
Please select the language of the Patient Information Booklet you would like to view below:
This booklet is also available to patients prescribed ELIQUIS via the patient section of the website.
Please click here to access the ELIQUIS Patient Information Leaflet.
BD = Twice Daily
DVT = Deep Vein Thrombosis
NVAF = Non-Valvular Atrial Fibrillation
PE = Pulmonary Embolism
SmPC = Summary of Product Characteristics
* ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor indicated for:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA);
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
- Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1
†Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.
Reference
- ELIQUIS® (apixaban) Summary of Product Characteristics.